Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,687.60
(
-0.46%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
112.08
(
5.16%
)
Bitcoin
69,983.87
(
-1.76%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 05/21/2007 5:25:27 PM

Monday, May 21, 2007 5:25:27 PM

Post# of 257257
SVR really is tantamount to a cure for HCV.

Roche reported today on a long-term follow-up study of patents who achieved SVR to prior therapy. Of the 997 patients followed for a mean duration of 4.1 years following an SVR, 989 of them (99.2%) were PCR-negative at the end of the follow-up period.

My guess is that some or all of the 8 patients who had detectable HCV were re-infected as opposed to having a relapse.

http://biz.yahoo.com/bw/070521/20070521006218.html?.v=1

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today